MDGEF (Medigene AG) Shares Buyback Ratio %: -13.96 (As of Sep. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGEF Medigene AG MDGEF
12 GF Score
Price $2.59
View Full Analysis

What is Medigene AG Shares Buyback Ratio %?

Medigene AG MDGEF 12 Shares Buyback Ratio % is -13.96 as of Sep. 17, 2026. GuruFocus rates MDGEF with a GF Score™ of 12/100.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Medigene AG's current shares buyback ratio was -13.96%.

Medigene AG Shares Buyback Ratio % Related Terms

Medigene AG Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Medigene AG's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG Shares Buyback Ratio % Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 0.00 0.00 0.00 0.00

Medigene AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -13.95
MDGEF
12GF Score
Medigene AG MDGEF
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG Shares Buyback Ratio % Calculation

Medigene AG's Shares Buyback Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2022 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Dec. 2022 )
=(12.932991398212 - 12.932991398212) / 12.932991398212
=0.00%

Medigene AG's Shares Buyback Ratio for the quarter that ended in Jun. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2023 ) - Shares Outstanding (EOP) (A: Jun. 2024 )) / Shares Outstanding (EOP) (A: Dec. 2023 )
=(12.932991398212 - 14.7375945) / 12.932991398212
=-13.95%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -13.96 mean?
Medigene AG (MDGEF) has a Shares Buyback Ratio % of -13.96 as of Sep. 17, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Medigene AG and its competitors.
Is Medigene AG's Shares Buyback Ratio % too high?
Medigene AG's current Shares Buyback Ratio % is -13.96. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's Shares Buyback Ratio % compare to VRTX and REGN?
Medigene AG's Shares Buyback Ratio % of -13.96 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Medigene AG and its competitors. Medigene AG's current Shares Buyback Ratio % is -13.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (MDGEF) has a current Shares Buyback Ratio % of -13.96. The current Shares Buyback Ratio % is -13.96. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Medigene AG (MDGEF), the current Shares Buyback Ratio % is -13.96 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for MDGEF

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price